7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

Inhalational anaesthetics exert widespread systemic effects across every major organ system while inducing general anaesthesia. Establishing clinical depth requires an objective pharmacological standard: the Minimum Alveolar Concentration (MAC). Alongside their therapeutic actions, volatile agents carry distinct organ toxicities and trigger lethal pharmacogenetic crises such as Malignant Hyperthermia.

---

1. MAC Concept, Mathematical Definitions, and Clinical Subtypes

Introduced by Eger and colleagues, Minimum Alveolar Concentration (MAC) is defined as the steady-state end-tidal alveolar concentration of an inhalational agent at 1 atmosphere (101.3 kPa / 760 mmHg) that prevents purposeful skeletal muscle movement in 50% of subjects in response to a standard supramaximal noxious stimulus (traditionally surgical skin incision).

$\text{MAC} = \text{Median Effective Dose } (ED_{50}) \text{ for immobility at } 1\text{ atmosphere}$

End-tidal alveolar partial pressure ($P_A$) is measured because at steady state, alveolar gas is in equilibrium with arterial blood and central nervous system tissue. Crucially, the immobility reflected by MAC is mediated primarily by action on ventral horn motor neurons and interneurons in the spinal cord, rather than cerebral cortex depression.

Clinical MAC Subtypes

• $\text{MAC}_{\text{awake}}$ (~0.3 to 0.4 MAC): The alveolar concentration at which 50% of patients open their eyes or execute appropriate voluntary responses to verbal command upon emergence. Corresponds to loss of recall and suppression of consciousness (amnesia).
• $\text{MAC}_{\text{BAR}}$ (~1.5 MAC): The alveolar concentration required to Blunt Autonomic Response (sympathetic surge, tachycardia, hypertension, pupillary dilation, and diaphoresis) to noxious surgical incision. Can be reduced dramatically to ~1.0 MAC with concurrent opioid administration.
• $\text{MAC}_{95}$ (~1.3 MAC): The alveolar concentration preventing purposeful movement in 95% of patients ($1.3 \times 1\text{ MAC}$). Typically targeted as the baseline clinical depth for surgical incision.
• $\text{MAC}_{\text{intubation}}$ (~1.3 to 1.5 MAC): The alveolar concentration preventing movement and coughing during endotracheal intubation in the absence of neuromuscular blocking drugs.
• Additivity of MAC: MAC fractions are strictly additive. For instance, administering 0.5 MAC of nitrous oxide (52%) alongside 0.5 MAC of sevoflurane (1.0%) delivers 1.0 MAC of total anaesthetic depth.

---

2. Factors Governing Minimum Alveolar Concentration

                    FACTORS MODULATING MAC
                              |
      +-----------------------+-----------------------+
      |                                               |
Factors Decreasing MAC                  Factors Increasing MAC
- Increasing age (~6%/decade)           - Hyperthermia (>38.5°C)
- Hypothermia (~5%/°C)                  - Hypernatremia
- Acute alcohol ingestion               - Chronic alcohol abuse
- Sedatives, Opioids, Ketamine          - Chronic amphetamine / cocaine abuse
- Alpha-2 agonists (clonidine, dex)     - Infant age (peak 1-6 months)
- Pregnancy / postpartum                - Acute amphetamine use
- Hypoxia (PaO2 < 38 mmHg)              - Red hair phenotype (MC1R mutation)
- Hypotension (MAP < 40 mmHg)
- Hyponatremia, Lithium, Lidocaine

FACTORS WITH NO EFFECT ON MAC: Gender, Duration of anaesthesia,
Arterial PaCO2 (20-95 mmHg), Hypertension, Thyroid status per se

Factors Decreasing MAC

1. Age: MAC peaks in infants aged 1 to 6 months and declines progressively thereafter. After age 40, MAC decreases by approximately 6% per decade of life due to progressive reductions in neuronal density, neurotransmitter synthesis, and cerebral metabolic rate.
2. Hypothermia: MAC decreases by ~5% per 1°C fall in core body temperature, reflecting decreased neuronal enzyme activity and enhanced gas solubility in tissues.
3. Acute Intoxication: Acute alcohol intake acts synergistically with $GABA_A$ transmission, markedly lowering MAC.
4. Adjuvant Drugs: Intravenous sedatives (propofol, benzodiazepines, barbiturates), opioids (which plateau at ~60-80% MAC reduction), and intravenous lidocaine.
5. $\alpha_2$-Adrenoceptor Agonists: Clonidine and dexmedetomidine produce dramatic, dose-dependent MAC reductions (up to 60-80%) via presynaptic $G_i$-mediated inhibition of locus coeruleus noradrenergic firing.
6. Pregnancy: Elevated circulating progesterone and endorphin levels reduce MAC by ~30-40% starting in the first trimester, returning to baseline within 24-72 hours postpartum.
7. Severe Physiological Derangements: Extreme arterial hypoxemia ($PaO_2 < 38\text{ mmHg} / 5\text{ kPa}$), severe arterial hypotension ($MAP < 40-50\text{ mmHg}$), hyponatremia (reduced CSF osmolarity), and metabolic acidosis.

Factors Increasing MAC

1. Hyperthermia: Elevated core temperature ($>38.5^\circ\text{C}$) increases MAC by ~5% per 1°C.
2. Hypernatremia: Elevated serum and CSF sodium concentrations increase central neuronal excitability.
3. Age: Highest MAC requirements occur in infants aged 1 to 6 months (sevoflurane 1 MAC is ~3.2-3.3% in infants vs 2.0% in 40-year-olds; neonates $<30$ days have slightly lower MAC than older infants).
4. Chronic Substance Abuse: Chronic alcoholism and chronic amphetamine or cocaine abuse upregulate central excitatory pathways and induce tolerance, shifting MAC higher.
5. Acute Sympathetic Stimulants: Acute amphetamine ingestion surges synaptic monoamine concentrations, raising MAC.
6. Red Hair Phenotype: Mutations in the melanocortin-1 receptor (MC1R) gene linked to pheomelanin production correlate with an ~19% increase in volatile anaesthetic requirement (desflurane).

Factors Having NO Direct Effect on MAC

• Gender / Biological Sex: MAC values do not differ significantly between males and females.
• Duration of Anaesthesia: Anaesthetic requirement does not decrease or increase with prolonged exposure.
• Arterial $PaCO_2$ (20 - 95 mmHg): Within this range, $PaCO_2$ does not change MAC. Only extreme hypercapnia ($PaCO_2 > 95-100\text{ mmHg}$) produces $CO_2$ narcosis, decreasing MAC.
• Hypertension: Baseline systemic arterial hypertension has no impact on MAC.
• Thyroid Status per se: Neither hyperthyroidism nor hypothyroidism directly alters neuronal MAC requirements. While hyperthyroidism increases cardiac output (which slows $F_A/F_I$ wash-in), intrinsic cerebral tissue sensitivity remains completely unaltered.

---

3. Organ System Effects: Cardiovascular and Hemodynamic Profiles

Cardiovascular Profiles of Modern Volatile Agents at 1 MAC:

Parameter         Sevoflurane      Isoflurane       Desflurane       Halothane
--------------------------------------------------------------------------------
Contractility     Decreased (++)   Decreased (++)   Decreased (++)   Decreased (+++)
SVR               Decreased (++)   Decreased (+++)  Decreased (+++)  Unchanged
Mean Art Pressure Decreased (++)   Decreased (++)   Decreased (++)   Decreased (+++)
Heart Rate        Unchanged / mild Moderate rise    Surges on rapid  Decreased / 
                  rise at >1 MAC   at >1 MAC        concentration ^  Bradycardia
Coronary Steal    Negligible       Arteriolar dil.  Negligible       None
                                   (theoretical)

Myocardial Depression and Vascular Resistance

All volatile anaesthetics produce dose-dependent myocardial depression by inhibiting sarcolemmal L-type calcium channels, attenuating calcium-induced calcium release from the sarcoplasmic reticulum, and decreasing myofibrillar calcium sensitivity:

• Isoflurane and Desflurane: Primarily lower mean arterial pressure ($MAP$) by causing direct systemic arteriolar vasodilation, resulting in marked reductions in Systemic Vascular Resistance (SVR).
• Sevoflurane: Causes modest SVR reduction and maintains cardiac output better than isoflurane at 1 MAC.
• Halothane: Leaves SVR largely unchanged but directly depresses myocardial contractility and stroke volume, dropping cardiac output by 30-50% at 1-1.5 MAC.

Baroreceptor Reflex and Desflurane Autonomic Surge

• Volatile agents blunt baroreceptor reflex sensitivity in a dose-dependent fashion, attenuating compensatory tachycardia during hypotension.
• Desflurane Tachycardia Surge: Rapid upward titration of desflurane concentration ($>1\text{ MAC}$ increment, e.g. stepping from 3% to 7%) stimulates sensory irritant receptors in the tracheobronchial tree, triggering reflex central sympathetic stimulation with transient surges in heart rate, arterial hypertension, and circulating norepinephrine. This surge can be mitigated by prior administration of intravenous fentanyl, esmolol, or clonidine.

The Coronary Steal Controversy

Isoflurane is a potent coronary arteriolar vasodilator, preferentially relaxing small resistance microvessels ($<100\ \mu\text{m}$). In theory, if a patient has a critical coronary stenosis with collateral-dependent myocardium where arterioles are already maximally dilated, dilating vessels in non-stenotic zones could divert blood away from the ischemic territory (the "coronary steal" phenomenon). However, extensive clinical trials confirm that coronary steal is virtually absent in clinical practice provided that coronary perfusion pressure is maintained ($MAP > 65-70\text{ mmHg}$).

---

4. Respiratory Mechanics and Airway Irritation

Ventilatory Pattern and Minute Ventilation

Volatile agents depress alveolar ventilation in a dose-dependent manner by direct actions on the medullary respiratory rhythm generator:

• Tidal Volume ($V_T$): Markedly reduced across all volatile agents.
• Respiratory Rate ($RR$): Compensatory increase (rapid, shallow breathing pattern), but insufficient to prevent a net drop in minute ventilation ($\dot{V}_E$).
• Arterial Carbon Dioxide ($PaCO_2$): Resting $PaCO_2$ rises progressively with increasing anaesthetic depth (apneic threshold shifts rightward).

Chemosensory Ventilatory Drives

• Hypercapnic Ventilatory Drive: The ventilatory response curve to elevated $CO_2$ is shifted to the right and its slope is markedly flattened. At 1.5-2.0 MAC, the hypercapnic drive is abolished.
• Hypoxic Ventilatory Drive: Peripheral chemoreceptors in the carotid bodies are exceptionally sensitive to inhalational agents. Sub-anaesthetic concentrations (0.1 MAC) suppress 50-70% of the hypoxic ventilatory response; 1.0 MAC completely extinguishes it. This leaves postoperative patients vulnerable to undetected hypoxemia in the post-anaesthesia care unit (PACU).

Bronchodilation vs Airway Pungency

• Bronchodilation: Volatile agents are potent direct bronchodilators, reversing acetylcholine- and histamine-induced bronchospasm by lowering intracellular calcium in bronchial smooth muscle (sevoflurane $\ge$ isoflurane > desflurane). Indicated for life-threatening refractory status asthmaticus.
• Airway Pungency: Sevoflurane has a sweet, non-pungent odor and does not irritate airway mucosa, making it the agent of choice for inhalational mask induction. In contrast, desflurane and isoflurane are pungent and irritating, triggering salivation, coughing, breath-holding, and severe laryngospasm if introduced without prior intravenous induction.

---

5. Central Nervous System Dynamics: Metabolism, Flow, and Epileptogenesis

CNS Uncoupling Effect (>1 MAC):

Physiological State: CMRO2 and CBF are coupled
  CMRO2 Decreases  ====>  CBF Decreases (Metabolic vasoconstriction)

Volatile Anaesthesia (>1 MAC): UNCOUPLING OCCURS
  CMRO2 Decreases  ====>  Neuronal depression (Isoelectric EEG at 1.5-2.0 MAC)
  Direct Vasodilation ===>  CBF INCREASES  ====>  ICP RISES

Management: Mild hyperventilation (PaCO2 30-35 mmHg) restores vasoconstriction

Cerebral Metabolic Rate ($CMRO_2$) and Cerebral Blood Flow (CBF)

• Volatile agents decrease cerebral metabolic rate for oxygen ($CMRO_2$) in a dose-dependent manner up to ~50% reduction, at which point an isoelectric (flatline) EEG is achieved (burst suppression occurs at 1.5-2.0 MAC).
• Direct intrinsic vascular action: Volatile agents are direct cerebral arteriolar vasodilators.
• The Uncoupling Phenomenon: At concentrations $<1\text{ MAC}$, metabolic suppression predominates, keeping CBF stable or reduced. At concentrations $>1\text{ MAC}$, direct intrinsic cerebral vasodilation overrides metabolic vasoconstriction, causing uncoupling: CBF increases despite a falling $CMRO_2$. The rise in CBF increases intracranial blood volume and intracranial pressure (ICP), especially in patients with space-occupying intracranial lesions.
• Mitigation: Mild hyperventilation to maintain $PaCO_2$ around 30-35 mmHg (4.0-4.7 kPa) preserves responsive cerebral vasoconstriction and blunts the rise in ICP.

Epileptogenic Potential of Sevoflurane

At high concentrations ($>1.5\text{ MAC}$), particularly when combined with hyperventilation (hypocapnia) during paediatric mask induction, sevoflurane can induce epileptiform electroencephalographic activity, including spike-and-wave patterns, burst suppression, and clinical myoclonic seizure-like motor activity. Desflurane and isoflurane do not possess epileptogenic potential; isoflurane is a potent anticonvulsant.

---

6. Specific Toxicities, Degradation, and Emergencies

Fluoride-Induced Nephrotoxicity

• Methoxyflurane: Extensively biotransformed (~50%) by hepatic CYP2E1, releasing large amounts of free inorganic fluoride ion ($F^-$). Serum $F^-$ concentrations exceeding $50\ \mu\text{mol/L}$ caused vasopressin-resistant high-output polyuric renal failure.
• Sevoflurane: Undergoes ~2-5% hepatic metabolism by CYP2E1, yielding fluoride ions and hexafluoroisopropanol (HFIP). Although serum $F^-$ can transiently exceed $50\ \mu\text{mol/L}$ after prolonged operations, sevoflurane does not cause nephrogenic diabetes insipidus or renal failure. Sevoflurane is metabolized almost exclusively in the liver rather than intrarenally, and inorganic fluoride is cleared rapidly without accumulating in renal medullary architecture.

Carbon Dioxide Absorbent Degradation: Compound A and Carbon Monoxide

Halothane Hepatitis

Halothane undergoes ~20% hepatic biotransformation via CYP2E1, producing a reactive acyl halide intermediate: trifluoroacetyl (TFA) chloride. TFA chloride covalently binds to hepatic microsomal proteins, forming trifluoroacetylated neoantigens. In genetically susceptible individuals, these neoantigens provoke an autoimmune, antibody-mediated cytotoxic T-cell response against hepatocytes upon re-exposure:

• Severe form presents 3-10 days post-exposure with fever, anorexia, jaundice, marked transaminitis ($AST/ALT > 10{,}000\text{ U/L}$), hepatic encephalopathy, and high mortality (~50-80%).
• Risk factors: Repeated exposures (especially within 3 months), female sex, obesity, and middle age.
• Modern fluorinated agents: Desflurane is metabolized ~0.02% to TFA and isoflurane ~0.2%; cross-reactivity is vanishingly rare. Sevoflurane is metabolized to HFIP, never forms TFA intermediates, and cannot cause TFA-mediated hepatitis.

Malignant Hyperthermia (MH) Crisis Management

Malignant Hyperthermia is a life-threatening, pharmacogenetic autosomal dominant skeletal muscle channelopathy primarily caused by mutations in the ryanodine receptor 1 gene (RYR1, chromosome 19q13.1) (~70-80% of cases) or the CACNA1S gene (voltage-gated dihydropyridine calcium channel).

MH Pathophysiology: Trigger (All Volatiles, Succinylcholine)
                         |
                         v
       Mutated RYR1 Calcium Channel in Sarcoplasmic Reticulum
                         |
                         v
       Uncontrolled Calcium Efflux into Skeletal Myoplasm
                         |
                         v
       Massive Actin-Myosin Cross-Bridging & Aerobic Hypermetabolism
                         |
     +-------------------+-------------------+
     |                                       |
Rapid CO2 Production, Rigidity       Lactic Acidosis, Temperature Spike (>42°C)
Hyperkalemia, Arrhythmias            Rhabdomyolysis, Renal Failure

• Triggers: ALL volatile inhalational anaesthetics (sevoflurane, desflurane, isoflurane, halothane) and the depolarizing muscle relaxant succinylcholine. Nitrous oxide, xenon, and all intravenous agents (propofol, opioids, ketamine, non-depolarizing relaxants) are safe non-triggers.
• Pathophysiology: Exposure to a trigger precipitates sustained, uncontrolled calcium release from the sarcoplasmic reticulum into the myoplasm. Intracellular calcium pumps and actomyosin ATPases work at maximal capacity, generating an extreme hypermetabolic crisis.
• Clinical Signs:
  • Earliest and most sensitive indicator: Unexplained, precipitous rise in end-tidal $\text{CO}_2$ ($ETCO_2$) refractory to progressive increases in minute ventilation.
  • Tachycardia, tachypnea, skin mottling, cyanosis.
  • Masseter muscle spasm (MMR) or generalized "board-like" skeletal muscle rigidity.
  • Hyperthermia: A late confirmation sign; core temperature can rise rapidly by $1-2^\circ\text{C}$ every 5 minutes, reaching $>42-43^\circ\text{C}$.
  • Mixed severe respiratory and metabolic lactic acidosis, hyperkalemia (fatal arrhythmias), and rhabdomyolysis with dark tea-colored myoglobinuria.

Immediate Crisis Protocol:

1. Cease Triggers: Immediately discontinue volatile agents and succinylcholine. Inform the surgical team to halt surgery immediately.
2. Hyperventilate: Administer 100% $\text{O}_2$ at high flows ($>10\text{ L/min}$) with a minute ventilation 2-3 times baseline. Attach activated charcoal filters to inspiratory and expiratory limbs of the circuit without delaying resuscitation.
3. Administer Dantrolene: Give Dantrolene sodium 2.5 mg/kg IV bolus immediately. Repeat boluses of 1.0-2.5 mg/kg every 5-10 minutes until hypercapnia, tachycardia, and rigidity resolve (cumulative doses up to 10 mg/kg or more). Dantrolene binds directly to the RYR1 receptor, halting intracellular calcium efflux.
4. Active Cooling: Infuse cold normal saline ($4^\circ\text{C}$), apply ice packs to axillae, groin, and neck, and initiate cold gastric/bladder lavage. Stop cooling when core temperature falls below $38.5^\circ\text{C}$ to prevent hypothermic rebound.
5. Treat Hyperkalemia: Administer calcium chloride (10 mg/kg), regular insulin (10 units) with 50 mL 50% dextrose, and sodium bicarbonate (1-2 mmol/kg).
6. Renal Protection: Maintain urine output $>2\text{ mL/kg/h}$ with intravenous fluids, mannitol, or furosemide to prevent myoglobin cast nephropathy.